# Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

> **NCT03367871** · PHASE2 · TERMINATED · sponsor: **University of Miami** · enrollment: 17 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03367871
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-06
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Investigator left institution
- **Last updated:** 2024-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367871, "Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03367871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*